Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 15, Issue 9, 2013, Pages 853-862

  Lambers Heerspink, H J ^a   De Zeeuw, D ^a   Wie, L ^c   Leslie, B ^b   List, J ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b BRISTOL MYERS SQUIBB   (United States)

^c Global Biometric Sciences   (United States)

Author keywords

Blood pressure; Dapagliflozin; HbA1c; Renal function; Type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CELLULITIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DIURETIC ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FAINTNESS; FEMALE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMATOPOIESIS; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA VOLUME; PLEURISY; RANDOMIZED CONTROLLED TRIAL; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; URINARY TRACT INFECTION;

BLOOD PRESSURE; DAPAGLIFLOZIN; HBA1C; RENAL FUNCTION; TYPE 2 DIABETES;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HUMANS; HYDROCHLOROTHIAZIDE; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84880850027     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12127     Document Type: Article

References (22)

1. Feinglos M, Dailey G, Cefalu W et al. Effect on glycemic control of the addition of 2.5mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract 2005; 68: 167-175.
2. Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes 2008; 116: 6-13.
3. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-1418.
4. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75: 1272-1277.
5. Komoroski B, Vachharajani N, Boulton D et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520-526.
6. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-519.
7. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657.
8. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
9. Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-1031.
10. Brochner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972; 30: 271-274.
11. Ogi M, Kojima S, Kuramochi M. Effect of postural change on urine volume and urinary sodium excretion in diabetic nephropathy. Am J Kidney Dis 1998; 31: 41-48.
12. Piuhola J, Kerkela R, Keenan JI, Hampton MB, Richards AM, Pemberton CJ. Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury. Clin Sci (Lond) 2008; 114: 293-304.
13. Gifford RW Jr, Mattox VR, Orvis AL, Sones DA, Rosevear JW. Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of aldosterone in hypertension. Circulation 1961; 24: 1197-1205.
14. Conway J, Lauwers P. Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation 1960; 21: 21-27.
15. Vallon V, Blantz RC, Thomson S. Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol 2003; 14: 530-537.
16. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 1999; 10: 2569-2576.
17. Pollock CA, Lawrence JR, Field MJ. Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus. Am J Physiol 1991; 260: F946-F952.
18. Christensen PK, Hansen HP, Parving HH. Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney Int 1997; 52: 1369-1374.
19. Gaspari F, Perico N, Matalone M et al. Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol 1998; 9: 310-313.
20. Ptaszynska A, Chalamandaris A-G, Sugg JE, Johnson KM, Parikh SJ, List J. Effect of Dapagliflozin on renal function [abstract]. Diabetes 2012; Suppl.
21. Kohan DE, Fioretto P, List J, Tang W. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment [abstract]. J Am Soc Nephrol 2011; 22: 232A.
22. Lambers Heerspink HJ, De Zeeuw D. Composite renal endpoints: was ACCOMPLISH accomplished? Lancet 2010; 375: 1140-1142.